The Drug That Kills Kids Without Warning, and Why Almost Nobody Covers It

In 2024, NIDA updated its inhalants research page for the first time since 2020. Not because something dramatic had changed in the science. But because a social media trend — teenagers calling nitrous oxide “galaxy gas” and filming themselves using it — had drawn enough attention that the agency needed to say something. That update, modest as it was, represents something close to the full extent of public attention that inhalant use receives in the United States, in a year when roughly 4.8 percent of 8th graders reported using an inhalant in the past year.

4.8 percent. That is not a small number. It means approximately one in twenty 13- and 14-year-olds have used an inhalant in the past twelve months — a rate that exceeds lifetime heroin use in the same age group by a significant margin. Among students who have ever tried any illegal or non-prescribed substance, inhalants are frequently among the first. And unlike alcohol, opioids, or stimulants, inhalants can kill on the first use.

Sudden Sniffing Death Syndrome — the cardiac arrest mechanism that occurs when volatile chemicals sensitize the heart to adrenaline, causing fatal arrhythmia — doesn’t wait for dependency to develop. It doesn’t warn. A young person who has never used anything before, who picks up a can of aerosol duster because it’s under the bathroom sink and free and takes effect in fifteen seconds, can die from a single session. Approximately 200 people die annually in the United States from inhalant abuse, per NIDA and SAMHSA surveillance data. The majority are under 25.

Why the treatment field keeps looking away

There is a structural reason that inhalants occupy almost no space in the addiction medicine conversation: the people who use them most are not the typical patient. They are young — middle school and high school age, with a peak around 8th grade, after which rates consistently decline. They are disproportionately low-income. They use substances that are not controlled, not scheduled, and not the focus of any pharmaceutical intervention.

The recovery ecosystem — treatment programs, detox facilities, medication-assisted treatment, telehealth — was built largely for adults with recognized dependence who have some capacity to self-advocate and have usually been using for years. Inhalant use, which typically peaks in early adolescence and declines sharply by late high school, doesn’t fit that model. The young people most at risk age out of the peak-risk window — or die — before they become someone’s insurance claim.

This produces a self-reinforcing research funding pattern. There are no approved medications for inhalant use disorder. There is no active pharmaceutical pipeline for inhalant dependence. NIDA funds inhalant research at levels that are several orders of magnitude below what it allocates to opioids, stimulants, or cannabinoids. The SAMHSA National Survey on Drug Use and Health tracks prevalence carefully. The field does almost nothing with the data.

The 50 to 80 percent cognitive impairment rate associated with regular inhalant use, cited consistently in NIDA’s research brief, rarely appears in clinical training programs. Prevention curricula mention inhalants, briefly, alongside other substances. Treatment programs for adolescents rarely have protocols specifically designed for inhalant dependence. The gap between what the epidemiology shows and what the clinical field has built to address it is one of the largest in addiction medicine.

What is actually happening in the brain

“Inhalants” is not a pharmacological category. It is a delivery method. The substances it covers are diverse, and they don’t all work the same way.

Volatile solvents — toluene, benzene, hexane, the core chemicals in glues, aerosols, and spray paints — work primarily on GABA receptors, producing sedation and disinhibition similar to alcohol. They also disrupt NMDA receptors and serotonin signaling. The intoxication comes on in seconds and lasts minutes, which makes the reinforcement schedule exceptionally powerful: the brain connects the action to the reward in a timeframe far shorter than alcohol or opioids.

Volatile solvents — toluene, benzene, hexane, the core chemicals in glues, aerosols, and spray paints — work primarily on GABA receptors, producing sedation and disinhibition similar to alcohol.

Nitrous oxide, now circulating as “galaxy gas” in youth social media, works primarily on NMDA receptors, producing dissociation and mild euphoria. The clinical presentation of heavy nitrous oxide use includes peripheral neuropathy from B12 depletion — a consequence that many young users don’t connect to their use until neurological symptoms appear.

Alkyl nitrites — amyl nitrite, commonly called “poppers” — work through a different mechanism entirely: smooth muscle relaxation, a brief circulatory effect, and a distinct rush. Their risk profile and user population differ substantially from volatile solvents or nitrous oxide.

The cognitive damage associated with long-term inhalant use — particularly volatile solvents — reflects white matter injury. Toluene is toxic to myelin, the insulating sheath that covers nerve fibers and allows signals to move quickly across the brain. Long-term users often develop a presentation that resembles the neurological impact of multiple sclerosis: memory impairment, slowed processing, difficulty with executive function, problems with balance. In adolescents, whose white matter development is not complete until the mid-20s, the damage is more severe and less reversible than in adults exposed to the same substance over the same period.

The psychology of why young people use inhalants

The psychology of inhalant use in adolescence speaks directly to why so many prevention programs fail to address it. Unlike heroin or methamphetamine, which carry cultural scripts and, among some populations, aspirational identities, inhalants are the substance of necessity — not aspiration.

Their use is more likely to be associated with boredom, social isolation, family instability, and limited access to other substances than with peer influence or identity formation. Research in Addiction has found that adolescents with housing instability, those in foster care or group home settings, and rural youth with limited social connection are significantly overrepresented among inhalant users. The intervention model that works for these populations is not a school-based curriculum. It is the same model that works for youth in crisis generally: stable housing, trusted adult relationships, economic supports for families.

This presents a specific problem for harm reduction approaches that have worked in adult populations. You cannot hand a 14-year-old in foster care a test strip and ask them to make an informed decision about their drug use. The environmental factors driving inhalant use in that population are upstream of any individual risk communication. Effective prevention has to address the conditions that make inhalants appealing — accessibility, immediacy, cost (free), and the absence of other options for relief — rather than the substance alone.

The “galaxy gas” trend and what it signals about the field

The nitrous oxide trend NIDA flagged in 2024 drew attention because it was visible and had a brand name. Nitrous oxide isn’t new — it has been available in whipped cream chargers and dental procedures for decades. Its current popularity among teenagers reflects something real: accessibility (widely available at retail, low cost), a risk profile that seems benign compared to fentanyl (and is, in limited use), and the way social platforms accelerate any behavior that has an aesthetic attached to it.

The real story in the nitrous trend is not the specific substance. It is the pattern: an inhalant enters popular culture, draws a brief wave of coverage, nothing structural changes, and then attention recedes. The young people who were using it before the trend are still using it after. The young people who started because of the trend continue outside the camera frame.

This is what the recovery field is bad at: the slow-moving, low-prestige crises that don’t fit a dramatic narrative. Inhalants don’t kill 70,000 people a year. They kill approximately 200, most of them young enough that their deaths don’t reach the data sets that drive federal funding formulas. They impair tens of thousands more in ways that surface years later, attributed to other causes, counted as other things.

They kill approximately 200, most of them young enough that their deaths don’t reach the data sets that drive federal funding formulas.

The question for anyone working in prevention, harm reduction, or adolescent care is not whether this is a lesser crisis. It is whether a crisis is worth addressing proportionally to the number of people it kills, or proportionally to the people — typically isolated, typically young, typically without access to the adults and resources that might intervene — who are at its center.

The inhalant data suggests the field has been answering that question incorrectly for a long time. The 200 annual deaths are not evenly distributed. They are concentrated in the populations for which the recovery ecosystem has the fewest tools and the least funding. That is where the work is.

For providers working with adolescent populations and looking for evidence-based screening and brief intervention resources: NIDA’s updated clinical guidelines and SAMHSA’s SBIRT framework include inhalants-specific protocols that most primary care providers have not reviewed since training.